Bottom line
Is IBRN a good fund? The bottom line
IBRN is an actively managed health care sector ETF from iShares.
It charges 0.47% — about $47 a year on every $10,000 invested, cheaper than 83% of health care sector funds we track.
It returned −2.7% over one year (as of Dec 31, 2024, per its prospectus).
With $5.5 million in net assets and 78 holdings, its largest position is BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (14.6%) and the top 10 make up 56.2% of the portfolio.
What stands out
- Low cost: cheaper than 83% of health care sector peers
What to watch
- Concentrated: top 10 holdings are 56.2% of assets
- Small fund ($5.5 million) — small funds are likelier to close
Updated Nov 19, 2026
What IBRN invests in
The iShares Neuroscience and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
The Fund seeks to track the investment results of the NYSE FactSet Global Neuro Biopharma and MedTech Index (the Underlying Index ), which measures the performance of equity securities of companies that are involved in the research, development or manufacturing of neurology biopharmaceuticals or neurological devices, as determined by ICE Data Indices, LLC or its affiliates (the Index Provider or IDI ). To be eligible for the Underlying Index, an equity security must (i) be listed in one of 44 developed and emerging market countries or regions, (ii) have a float-adjusted market capitalization of at least $100 million and (iii) have a three-month average daily trading value ( ADTV ) of at least $1 million. Existing constituents may remain in the Underlying Index with a float-adjusted market capitalization of at least $75 million and a three-month ADTV of at least $750,000 at each index…
From the fund's prospectus (filed Nov 21, 2025).
IBRN performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| IBRN | −2.7% | — | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What IBRN costs
On a $10,000 investment, IBRN's 0.47% expense ratio costs about $47 a year. The prospectus estimates $591 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
IBRN top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 14.64% |
| 2 | Dianthus Therapeutics Inc | 5.34% |
| 3 | Xenon Pharmaceuticals Inc | 4.87% |
| 4 | Praxis Precision Medicines Inc | 4.87% |
| 5 | Acadia Pharmaceuticals Inc. | 4.69% |
| 6 | Arrowhead Pharmaceuticals, Inc. | 4.65% |
| 7 | Alkermes Public Limited Company | 4.60% |
| 8 | Scholar Rock Holding Corp | 4.29% |
| 9 | Biogen Inc. | 4.18% |
| 10 | Neurocrine Biosciences, Inc. | 4.09% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 56.2% of the fund. See all top 25 holdings and asset mix →